Objective: This systematic review and meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association. Methods: A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8 October 2020. This study’s main outcome is a poor composite outcome, comprising of mortality and severe COVID-19. Results: There were 9 studies with 3663 patients. The prevalence of dyslipidemia in this pooled analysis was 18% (4%-32%). Dyslipidemia was associated with increased composite poor outcome (RR 1.39 [1.02, 1.88], P =.010; I2: 56.7%, P =.018). Subgroup analysis showed that dyslipidemia was associated with severe COVID-19 (RR 1.39 [1.03, 1.87], P =.008; I2: 57.4%, P =.029). Meta-regression showed that the association between dyslipidemia and poor outcome varies by age (coefficient: −0.04, P =.033), male gender (coefficient: −0.03, P =.042), and hypertension (coefficient: −0.02, P =.033), but not diabetes (coefficient: −0.24, P =.135) and cardiovascular diseases (coefficient: −0.01, P =.506). Inverted funnel-plot was relatively symmetrical. Egger’s test indicates that the pooled analysis was not statistically significant for small-study effects (P =.206). Conclusion: Dyslipidemia potentially increases mortality and severity of COVID-19. The association was stronger in patients with older age, male, and hypertension. PROSPERO Registration Number: CRD42020213491 © The Author(s) 2021.